Clinical Trial Update: Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports the evaluation of overall survival for Meclinertant versus placebo after first-line cisplatin plus etoposide in lung cancer i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Meclinertant (Meclinertant)

Snippet

Sponsor: Sanofi | Conditions: Lung Cancer, Pulmonary Neoplasms | Phase 2, Phase 3 | Status: COMPLETED